I spoke to the Guy who did the Ru58841 (PSK-3841) research Research/Science 5/18/2021
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
View this post in the Community →
Similar Community Posts Join
5 / 1000+ resultscommunity ~5 months topical minoxidil + oral finasteride results (swipe images). Slacked with minoxidil this past month, trying to wean off anyways. My last update because I’m hopping off fin and switching to RU in a few weeks (nothing to do with fin efficacy, just experimenting).
The user experienced significant hair thickening after using topical minoxidil and oral finasteride for about 5 months and is considering switching from finasteride to RU58841. Other users encourage the original poster to continue the current treatment due to the positive results.
community Switch from fin to dut and its worse
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
community 2 years on dut (.5mg three times per week) 1 and a half on RU 5% (once a day)
The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.
community Safety of RU-58841: I talked to the Pharma Company that researched it, Human Clinical Trials, and Potential Reasons for Discontinuation
The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.
community Research about RU58841 /Why it was stopped
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
Related Research
6 / 546 results
research Experimental and Early Investigational Drugs for Androgenetic Alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research Investigational Medications in the Treatment of Alopecia
New treatments for hair loss are being developed using molecular biology.
research Types of Hair Loss and Treatment Options, Including the Novel Low-Level Light Therapy and Its Proposed Mechanism
Hair loss treatments include medications and new methods like low-level light therapy, which may work by boosting cell activity and blood flow.
research Antiandrogens and Androgen Inhibitors in Dermatologic Treatments
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.